drugset

drugset / Trial / NCT03362177

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

NCT03362177 ↗

Phase 3 Completed 165 enrolled Amgen

RandomizedParallel-groupDouble-blindTreatment

Summary

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer

Timeline

Start: 2019-09-30
Primary completion: 2024-01-25
Completion: 2025-01-09

Publications

Al-Samkari H, Munoz C, Geredeli C, Korantzis I, Gonzalez Astorga B, Arslan C, Cordeiro Camargo JF, Scotte F, Borges G, Wang K, Eisen M, Kuter DJ, Soff GA. Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia. N Engl J Med. 2026 Mar 12;394(11):1061-1073. doi: 10.1056/NEJMoa2511882.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Romiplostim	Peptide	—	Subcutaneous

Indications